CDRH names Jacobson acting director

Article

Just weeks after the Center for Devices and Radiological Health announced that Dr. Bruce Burlington would be leaving his post as director in March, the agency named Elizabeth Jacobson as acting director. Food and Drug Administration Commissioner Dr. Jane

Just weeks after the Center for Devices and Radiological Health announced that Dr. Bruce Burlington would be leaving his post as director in March, the agency named Elizabeth Jacobson as acting director. Food and Drug Administration Commissioner Dr. Jane Henney announced Burlington’s departure in January (SCAN 2/3/99) and appointed Jacobson as his temporary successor last month. Henney continues to seek a permanent replacement for the position.

Jacobson arrived at the FDA’s Bureau of Radiological Health in 1975 as a research geneticist. She has held several scientific and management posts at the Bureau and the CDRH, including director of the Office of Science and Technology and deputy director for science at the CDRH. Jacobson has served as acting director at the CDRH once before, from December 1992 to February 1993.

Jacobson will begin her tenure as acting director on March 13, when Burlington leaves for a new post as head of regulatory affairs at Wyeth-Ayerst Pharmaceuticals in Philadelphia.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.